N1-Methylpseudouridine
N1-Methylpseudouridine (abbreviated m1Ψ) is a natural tRNA component[1] as well as a synthetic pyrimidine nucleoside used in biochemistry and molecular biology for in vitro transcription and is found in the SARS-CoV-2 mRNA vaccines tozinameran (Pfizer–BioNTech) and elasomeran (Moderna).
![]() | |
| Names | |
|---|---|
| IUPAC name
5-[(2S,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1-methylpyrimidine-2,4-dione | |
| Other names
1-Methylpseudouridine; m1Ψ | |
| Identifiers | |
3D model (JSmol) |
|
| ChEBI | |
| ChemSpider | |
PubChem CID |
|
| UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
| Properties | |
| C10H14N2O6 | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
Properties
N1-Methylpseudouridine is the methylated derivative of pseudouridine. It is used in in vitro transcription and for the production of RNA vaccines,[2][3] In vertebrates, it stimulates significantly less activation of the innate immune response compared to uridine.[4] At the same time, the translation is stronger.[5][6] In protein biosynthesis, it is read like uridine and enables comparatively high protein yields.[6][7] In 2016, a protocol for large-scale synthesis of the nucleoside triphosphate from the ribonucleoside was published.[8] The nucleoside itself can be made by chemical methylation of pseudouridine.[9]
References
- Jan Philip Wurm, Marco Griese, Ute Bahr, Martin Held, Alexander Heckel, Michael Karas, Jörg Soppa, Jens Wöhnert (Mar 2012). "Identification of the enzyme responsible for N1-methylation of pseudouridine 54 in archaeal tRNAs". RNA. 18 (3): 412–420. doi:10.1261/rna.028498.111. PMC 3285930. PMID 22274954.CS1 maint: multiple names: authors list (link)
- Knudson CJ, Alves-Peixoto P, Muramatsu H, Stotesbury C, Tang L, Lin PJ, et al. (May 2021). "Lipid-nanoparticle-encapsulated mRNA vaccines induce protective memory CD8 T cells against a lethal viral infection". Molecular Therapy. doi:10.1016/j.ymthe.2021.05.011. PMID 33992803.
- Krienke C, Kolb L, Diken E, Streuber M, Kirchhoff S, Bukur T, et al. (January 2021). "A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis". Science. 371 (6525): 145–153. Bibcode:2021Sci...371..145K. doi:10.1126/science.aay3638. PMID 33414215. S2CID 231138578.
- Nelson J, Sorensen EW, Mintri S, Rabideau AE, Zheng W, Besin G, et al. (June 2020). "Impact of mRNA chemistry and manufacturing process on innate immune activation". Science Advances. 6 (26): eaaz6893. Bibcode:2020SciA....6.6893N. doi:10.1126/sciadv.aaz6893. PMC 7314518. PMID 32637598.
- Andries O, Mc Cafferty S, De Smedt SC, Weiss R, Sanders NN, Kitada T (November 2015). "N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice". Journal of Controlled Release. 217: 337–44. doi:10.1016/j.jconrel.2015.08.051. hdl:1854/LU-6993270. PMID 26342664.
- Svitkin YV, Cheng YM, Chakraborty T, Presnyak V, John M, Sonenberg N (June 2017). "N1-methyl-pseudouridine in mRNA enhances translation through eIF2α-dependent and independent mechanisms by increasing ribosome density". Nucleic Acids Research. 45 (10): 6023–6036. doi:10.1093/nar/gkx135. PMC 5449617. PMID 28334758.
- Parr CJ, Wada S, Kotake K, Kameda S, Matsuura S, Sakashita S, et al. (April 2020). "N 1-Methylpseudouridine substitution enhances the performance of synthetic mRNA switches in cells". Nucleic Acids Research. 48 (6): e35. doi:10.1093/nar/gkaa070. PMC 7102939. PMID 32090264.
- Shanmugasundaram M, Senthilvelan A, Kore AR (December 2016). "Gram-Scale Chemical Synthesis of Base-Modified Ribonucleoside-5'-O-Triphosphates". Current Protocols in Nucleic Acid Chemistry. 67: 13.15.1–13.15.10. doi:10.1002/cpnc.20. PMID 27911496. S2CID 5143935.
- Robert A. Earl, Leroy B. Townsend (Jun 1977). "A chemical synthesis of the nucleoside 1-methylpseudouridine". Journal of Heterocyclic Chemistry.
